Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting a specific transaction within a retirement plan and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported change is an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on August 2, 2013.
- Transaction Price: The ADS price was $52.22 per share.
- Parties Involved: The transaction involved Dr. M. Slaoui (Director) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs, while Dr. K. Slaoui received an allocation of 4 ADSs.
- Plan Context: The transaction relates to the GSK 401K plan, which is notionally held in GSK ADSs.